Advertisement
| car t cell therapy lymphoma success rate: The EBMT/EHA CAR-T Cell Handbook Nicolaus Kröger, John Gribben, Christian Chabannon, Ibrahim Yakoub-Agha, Hermann Einsele, 2022-02-07 This first open access European CAR-T Handbook, co-promoted by the European Society for Blood and Marrow Transplantation (EBMT) and the European Hematology Association (EHA), covers several aspects of CAR-T cell treatments, including the underlying biology, indications, management of side-effects, access and manufacturing issues. This book, written by leading experts in the field to enhance readers’ knowledge and practice skills, provides an unparalleled overview of the CAR-T cell technology and its application in clinical care, to enhance readers’ knowledge and practice skills. |
| car t cell therapy lymphoma success rate: Chimeric Antigen Receptor T-Cell Therapies for Cancer E-Book Daniel W. Lee, Nirali N. Shah, 2019-11-30 From patient referral to post-therapy management, Chimeric Antigen Receptor (CAR) T-Cell Therapies for Cancer: A Practical Guide presents a comprehensive view of CAR modified T-cells in a concise and practical format. Providing authoritative guidance on the implementation and management of CAR T-cell therapy from Drs. Daniel W. Lee and Nirali N. Shah, this clinical resource keeps you up to date on the latest developments in this rapidly evolving area. - Covers all clinical aspects, including patient referral, toxicities management, comorbidities, bridging therapy, post-CAR monitoring, and multidisciplinary approaches to supportive care. - Includes key topics on associated toxicities such as predictive biomarkers, infections, and multidisciplinary approaches to supportive care. - Presents current knowledge on FDA approved CAR T-cell products as well as developments on the horizon. - Editors and authors represent leading investigators in academia and worldwide pioneers of CAR therapy. |
| car t cell therapy lymphoma success rate: Blood and Marrow Transplant Handbook Richard T. Maziarz, Susan Schubach Slater, 2015-04-20 This updated and expanded edition developed by the Blood and Marrow Stem Cell Transplant team at Oregon Health & Science University Knight Cancer Institute features the latest medical management guidelines and standards of care for hematopoietic stem cell transplant patients. Spanning the timeline from the initial consultation throughout the transplant process, this handbook includes indications for transplantation and donor selection, treatment guidelines for addressing complications during and after transplant, and recommendations for long-term follow up care. Concise, comprehensive, and easy-to-use, Blood and Marrow Transplant Handbook, 2nd Edition presents a multidisciplinary approach to information for physicians and advanced practice medical providers who care for transplant patients, and also residents, fellows, and other trainees. |
| car t cell therapy lymphoma success rate: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice MiKaela M. Olsen, Kristine B. LeFebvre, Suzanne L. Walker, Elizabeth Prechtel Dunphy, 2022 Oncology nursing is a unique specialty that requires continuous learning to stay up to date on cancer pathophysiology, cutting-edge drugs, and the evidence-based management of cancer and cancer treatment-related toxicities. The Oncology Nursing Society's (ONS's) second edition of Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice provides nurses with the tools to understand how medications are used in cancer treatment, the effect of medication-related toxicities, and evidence-based recommendations to manage and treat these toxicities. This edition features many new cancer therapies approved since the 2019 publication. Each drug is categorized as chemotherapy, hormone, targeted, or immunotherapy agents. Extensive drug tables in the book provide nurses with tips for managing patients receiving these drugs. The expansion of oral antineoplastic therapies, alone or in combination with infusion therapy, requires that nurses review a patient's complete cancer treatment plan and consider the side effects, toxicities, and adherence to oral drugs to ensure patient tolerance and efficacy. This second edition has seen content expanded on the topic of genomics as we move forward in the world of personalized oncology. Health equity is approached with information discussing financial distress, cultural disparities, and health literacy. The latest guidelines and recommendations for treatment, symptom management, and survivorship have been integrated into this new text. This edition features a QR code, provided with the purchase of this book, to download quarterly drug updates. You will see new evidence related to many aspects of cancer nursing care incorporated into this edition, such as hypersensitivity response, safe handling of hazardous drugs, and more. The editors want to thank all of the contributors to this edition who worked tirelessly, despite a pandemic, to make this new edition a reality. This work builds on the knowledge of many generations of oncology nurses and has been used nationally and internationally to guide oncology nursing practice. We are proud to continue to serve oncology nurses worldwide with an essential resource to guide their practice-- |
| car t cell therapy lymphoma success rate: Autologous Stem Cell Transplantation Angelo Carella, 2020-08-26 This textbook integrates basic research and clinical aspects underlying the most recent results in those malignant diseases where progress is most effective. Recent evidence shows that higher doses are better in inducing higher cure rates in hematological neoplasias, although myeloblation related to dose intensity can be a limiting factor. The toxicity can now be controlled with autologous marrow and peripheral blood progenitor cell transplantation, used with or without growth factors. The combination of high dose chemoradiotherapy followed by re-infusion of autologous stem cells constitute a dramatic advance in the treatment of refactory and relapse hematological neoplasias. |
| car t cell therapy lymphoma success rate: Guide to Immunotherapy Suzanne L. Walker, Elizabeth Prechtel Dunphy, 2018-10 |
| car t cell therapy lymphoma success rate: Report to the Congress, Medicare Payment Policy Medicare Payment Advisory Commission (U.S.), 1998 |
| car t cell therapy lymphoma success rate: Childhood Acute Lymphoblastic Leukemia Ajay Vora, 2017-04-21 This book provides a comprehensive and up-to-date review of all aspects of childhood Acute Lymphoblastic Leukemia, from basic biology to supportive care. It offers new insights into the genetic pre-disposition to the condition and discusses how response to early therapy and its basic biology are utilized to develop new prognostic stratification systems and target therapy. Readers will learn about current treatment and outcomes, such as immunotherapy and targeted therapy approaches. Supportive care and management of the condition in resource poor countries are also discussed in detail. This is an indispensable guide for research and laboratory scientists, pediatric hematologists as well as specialist nurses involved in the care of childhood leukemia. |
| car t cell therapy lymphoma success rate: Drug Resistance in Leukemia & Gert-Jan L. Kaspers, 1993-01-01 The last ten years have seen the publication of a vast amount of data regarding cellular resistance to drugs in cancer cells. Recent studies have demonstrated that drug resistance assays appear to be predictive of clinical response and suggest that clinicians should now be considering the potential applications of these assays in the treatment of patients with hematological neoplasms. This collection of papers from the International Symposium on the Clinical Value of Drug Resistance Assays in Leukemia and Lymphoma, Amsterdam, 1992, provides a state-of-the-art discussion on drug resistance assays and their role in the design and individualization of treatment protocols. |
| car t cell therapy lymphoma success rate: Co-signal Molecules in T Cell Activation Miyuki Azuma, Hideo Yagita, 2019-11-22 This book equips young immunologists and health professionals with a clear understanding of the fundamental concepts and roles of co-signal molecules and in addition presents the latest information on co-stimulation. The first part of the book is devoted to co-signal molecules and the regulation of T cells. Following an initial overview, subsequent chapters examine each co-signal molecule in turn and discuss the mechanisms by which co-signal molecules regulate the different types of T cell. The second part covers various clinical applications, including in autoimmune disease, neurological disorders, transplantation, graft-versus-host disease, and cancer immunotherapy. To date, co-stimulation blockade and co-inhibition blockade have shown beneficial effects and many additional clinical trials targeting co-signal molecules are ongoing. The mechanisms underlying these successful treatments are explained and the future therapeutic potential in the aforementioned diseases is evaluated. Co-signal Molecules in T Cell Activation will be a valuable reference guide to co-stimulation for basic and clinical researchers in the fields of both immunology and pharmaceutical science. |
| car t cell therapy lymphoma success rate: Fast Facts: CAR T-Cell Therapy in Diffuse Large B-Cell Lymphoma R.J. Buka, D. Moloney, 2021-09-30 Diffuse large B-cell lymphoma (DLBCL) is the most common form of high-grade non-Hodgkin lymphoma. While treatment with immunochemotherapy has generally shown good outcomes, specific subgroups of patients with high-risk disease have an unfavorable prognosis. Extensive efforts have been made to improve outcomes in these patients. As such, CD19-targeted chimeric antigen receptor (CAR) T-cell therapy has become the new standard of care for patients with relapsed or refractory DLBCL after at least two prior lines of therapy. It is an exciting new therapeutic intervention that is integral to the concept of personalized medicine. Table of Contents: • DLBCL: an overview • CAR T cells • CAR T-cell products • Delivering CAR T-cell therapy and managing patient expectations • CAR T-cell therapy-related toxicities |
| car t cell therapy lymphoma success rate: Heparanase Israel Vlodavsky, Ralph D. Sanderson, Neta Ilan, 2020-04-09 Written by internationally recognized leaders in Heparanase biology, the book’s eight chapters offer an opportunity for scientists, clinicians and advanced students in cell biology, tumor biology and oncology to obtain a comprehensive understanding of Heparanase’s multifaceted activities in cancer, inflammation, diabetes and other diseases, as well as its related clinical applications. Proteases and their involvement in cancer progression have been well addressed and documented; however, the emerging premise presented within this book is that Heparanase is a master regulator of aggressive cancer phenotypes and crosstalk with the tumor microenvironment. This endoglycosidase contributes to tumor-mediated remodeling of the extracellular matrix and cell surfaces, augmenting the bioavailability of pro-tumorigenic and pro-inflammatory growth factors and cytokines that are bound to Heparan sulfate. Compelling evidence ties Heparanase with all steps of tumor progression including tumor initiation, growth, angiogenesis, metastasis, and chemoresistance, supporting the notion that Heparanase is an important contributor to the poor outcome of cancer patients and a validated target for therapy. Unlike Heparanase, heparanase-2, a close homolog of Heparanase, lacks enzymatic activity, inhibits Heparanase, and regulates selected genes that promote normal differentiation and tumor suppression. Written by internationally recognized leaders in Heparanase biology, this volume presents a comprehensive understanding of Heparanase’s multifaceted activities in cancer, inflammation, diabetes and other diseases, as well as its related clinical applications to scientists, clinicians and advanced students in cell biology, tumor biology and oncology. |
| car t cell therapy lymphoma success rate: Haploidentical Transplantation Stefan O. Ciurea, Rupert Handgretinger, 2018-05-03 In this book, world-renowned experts in the field express well-reasoned opinions on a range of issues and controversies relating to haploidentical transplantation with the aim of providing practicing hematologists with clinically relevant and readily applicable information. Among the areas covered are graft manipulation and methods to control T-cell alloreactivity, the nature of the ideal graft and donor, haploidentical transplantation in pediatric and adult patients with malignant and nonmalignant diseases, immunologic reconstitution following transplantation, complications, and the prevention and treatment of relapse post transplantation. Attention is drawn to the implications of high-impact clinical trials whenever such trials are available. The readily intelligible text is complemented by numerous helpful tables, algorithms, and figures. The book will provide practical support for hematologists and transplant physicians as they attempt to provide optimal care in this exciting but increasingly complex medical specialty. |
| car t cell therapy lymphoma success rate: The Peripheral T-Cell Lymphomas Owen A. O'Connor, Won Seog Kim, Pier L. Zinzani, 2021-06-01 THE PERIPHERAL T-CELL LYMPHOMAS Provides a comprehensive look at Peripheral T-Cell lymphomas, including the group’s unique geographic distribution, underlying genetics, and novel treatments Peripheral T-Cell lymphomas (PTCL) are a diverse group of lymphoid malignancies that develop from mature T cells and natural killer (NK) cells. PTCL represent 10-15% of all cases of non-Hodgkin lymphoma in the US, and up to 20-25% of cases in South America, Asia, and other regions around the world. The role of different etiologic factors and the variation of geographic distribution makes PTCL one of the most difficult types of cancer to understand and treat. For the first time in a single volume, The Peripheral T-Cell Lymphomas presents a comprehensive survey of this complex and rare group of blood cancers. Featuring contributions from an international team of leading authorities in the various aspects of PTCL, this authoritative text covers biology, epidemiology, classification, approved and emerging drugs, molecular genetics, and more. Detailed clinical chapters address diagnosis, prognosis, and treatment of each of the major PTCL subtypes identified in the 2018 WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues. This much-needed resource: Covers the biological basis, epidemiology, classification, and treatment of PTCL Discusses the future of the field, including global collaboration efforts and novel approaches to PCTL Explores the role of biologics in PTCL and autologous and allogeneic stem-cell transplantation Offers new insights on molecular pathogenesis, innovative therapeutics, and novel drug combinations Features contributions from the Chairs The T-Cell Lymphoma Forum: the world’s largest meeting focused on PTCL Reflecting the unique epidemiology and genetic diversity of the PTCL, The Peripheral T-Cell Lymphomas is an indispensable source of data, insight, and references for the medical community, particularly oncologists and hematologists in both training and practice. |
| car t cell therapy lymphoma success rate: Radiation Oncology Frederik Wenz, 2023-08-29 In this Handbook, a team of leading experts provide a comprehensive and up-to-date overview of the ever-changing field of radiation oncology. The publication is divided into three volumes, the first of which covers basics such as radiotherapy techniques, treatment documentation, clinical radiobiology, and patient management. In the second volume, all aspects of clinical radiation therapy are discussed in depth for the full range of tumor types. In order to ensure that the reader has a full understanding of cancer management in each scenario, information is also provided on diagnosis and classification, general management principles, the role of surgical and systemic therapy, and prognosis. The third volume focuses on medical physics, covering the mathematical and computer science background, biophysics, radiation physics, instrumentation, tracer kinetic modeling, pharmacokinetics and pharmacodynamics, radiation sources and detectors, biomedical engineering, imaging techniques, radiation treatment planning, and quality assurance. This book will be invaluable for all radiation oncologists. It is published as part of the SpringerReference program, which delivers access to living editions constantly updated through a dynamic peer-review publishing process. |
| car t cell therapy lymphoma success rate: Oncoimmunology Laurence Zitvogel, Guido Kroemer, 2017-12-13 In this book, leading experts in cancer immunotherapy join forces to provide a comprehensive guide that sets out the main principles of oncoimmunology and examines the latest advances and their implications for clinical practice, focusing in particular on drugs with FDA/EMA approvals and breakthrough status. The aim is to deliver a landmark educational tool that will serve as the definitive reference for MD and PhD students while also meeting the needs of established researchers and healthcare professionals. Immunotherapy-based approaches are now inducing long-lasting clinical responses across multiple histological types of neoplasia, in previously difficult-to-treat metastatic cancers. The future challenges for oncologists are to understand and exploit the cellular and molecular components of complex immune networks, to optimize combinatorial regimens, to avoid immune-related side effects, and to plan immunomonitoring studies for biomarker discovery. The editors hope that this book will guide future and established health professionals toward the effective application of cancer immunology and immunotherapy and contribute significantly to further progress in the field. |
| car t cell therapy lymphoma success rate: Cancer Immunology and Immunotherapy Mansoor M. Amiji, Lara Scheherazade Milane, 2021-08-18 Delivery Technologies for Immuno-Oncology: Volume 1: Delivery Strategies and Engineering Technologies in Cancer Immunotherapy examines the challenges of delivering immuno-oncology therapies. Immuno-oncology (IO) is a growing field of medicine at the interface of immunology and cancer biology leading to development of novel therapeutic approaches, such as chimeric antigen receptor T-cell (CAR-T) and immune checkpoint blockade antibodies, that are clinically approved approaches for cancer therapy. Although currently approved IO approaches have shown tremendous promise for select types of cancers, broad application of IO strategies could even further improve the clinical success, especially for diseases such as pancreatic cancer, brain tumors where the success of IO so far has been limited. Nanotechnology-based targeted delivery strategies could improve the delivery efficiency of IO agents as well as provide additional avenues for novel therapeutic and vaccination strategies. Additionally, a number of locally-administered immunogenic scaffolds and therapeutic strategies, such as the use of STING agonist, could benefit from rationally designed biomaterials and delivery approaches. Delivery Technologies for Immuno-Oncology: Volume 1: Delivery Strategies and Engineering Technologies in Cancer Immunotherapy creates a comprehensive treaty that engages the scientific and medical community who are involved in the challenges of immunology, cancer biology, and therapeutics with possible solutions from the nanotechnology and drug delivery side. - Comprehensive treaty covering all aspects of immuno-oncology (IO) - Novel strategies for delivery of IO therapeutics and vaccines - Forecasting on the future of nanotechnology and drug delivery for IO |
| car t cell therapy lymphoma success rate: Developing Costimulatory Molecules for Immunotherapy of Diseases Manzoor Ahmad Mir, 2015-05-25 Developing Costimulatory Molecules for Immunotherapy of Diseases highlights the novel concept of reverse costimulation and how it can be effectively exploited to develop immunotherapy using either humanized antibodies against CD80, CD86, and other costimulatory molecules or CD28 fusinogenic proteins in the treatment of diseases, including allergies, asthma, rheumatoid arthritis, multiple sclerosis, lupus nephritis, severe psoriasis, vulgaris tuberculosis, thopoid, transplantation therapeutic, cancer, and inflammation. The text aims to provide the latest information on the complex roles and interactions within the CD28 and B7 costimulatory families, with the hope that targeting these families will yield new therapies for the treatment of inflammation, autoimmunity, transplantation, cancer, and other infectious diseases. - Highlights the novel concept of reverse costimulation and how it can be effectively exploited to develop immunotherapy - Provides the latest information on the complex roles and interactions within the CD28 and B7 costimulatory families - Targets new therapies for the treatment of inflammation, autoimmunity, transplantation, cancer, and other infectious diseases |
| car t cell therapy lymphoma success rate: Peripheral T-cell Lymphomas Pier Paolo Piccaluga, 2019-08-07 In this book the reader will find a collection of chapters written by different research teams describing different aspects of peripheral T-cell lymphoma pathobiology, classification, and treatment. This work is mainly addressed to researchers already working in this area, but it is also accessible to anyone with a scientific background who desires to have an updated overview of the recent progress in this domain. It will also be valuable to scientists and physicians who have become newly involved in this field. Each chapter is self-contained and can be read independently of the others. This book intends to provide highlights of the current research as well as the current gold standards for diagnosis and treatment of these diseases, showing the recent advances in the personalized approach to T-cell derived lymphomas. |
| car t cell therapy lymphoma success rate: Epstein Barr Virus Volume 2 Christian Münz, 2015-10-01 Epstein Barr virus (EBV) was discovered as the first human tumor virus around 50 years ago. Since its discovery in Burkitt’s lymphoma it has been associated with various other malignancies, infectious mononucleosis and even autoimmune diseases. The two book volumes on EBV summarize the first 50 years of research on this tumor virus, starting with historical perspectives on discovery, oncogenicity and immune control, reviewing the role that the virus plays in the various associated diseases and concluding with a discussion on how the immune system keeps persistent EBV infection under control in healthy EBV carriers and can be used to treat EBV associated diseases. The respective 32 chapters are written by international experts from three continents for health care providers, biomedical researchers and patients that are affected by EBV. The assembled knowledge should help to understand EBV associated diseases better and to develop EBV specific vaccination in the near future. |
| car t cell therapy lymphoma success rate: A Mild Touch of the Cancer David Downs, 2019-08 An amazing account of Davids battle with terminal cancer, as documented in a highly successful blog, with over 100,000 followers. (Spoiler alert he lived.) With guest sections by some of NZs most well-known comedians, including Jeremy Corbett, Michele ACourt and Paul Ego, and an introduction by The Amazing Races Phil Keoghan. Written with joy, curiosity and humour, this isn't a story about cancer, its a story about living with optimism. By the successful author of popular books No.8 Rewired and No.8 Recharged |
| car t cell therapy lymphoma success rate: The Comprehensive Cancer Center Mahmoud Aljurf, Navneet S. Majhail, Mickey B.C. Koh, Mohamed A. Kharfan-Dabaja, Nelson J. Chao, 2021-10-28 This open access book provides a valuable resource for hospitals, institutions, and health authorities worldwide in their plans to set up and develop comprehensive cancer care centers. The development and implementation of a comprehensive cancer program allows for a systematic approach to evidence-based strategies of prevention, early detection, diagnosis, treatment, and palliation. Comprehensive cancer programs also provide a nexus for the running of clinical trials and implementation of novel cancer therapies with the overall aim of optimizing comprehensive and holistic care of cancer patients and providing them with the best opportunity to improve quality of life and overall survival. This book's self-contained chapter format aims to reinforce the critical importance of comprehensive cancer care centers while providing a practical guide for the essential components needed to achieve them, such as operational considerations, guidelines for best clinical inpatient and outpatient care, and research and quality management structures. Intended to be wide-ranging and applicable at a global level for both high and low income countries, this book is also instructive for regions with limited resources. The Comprehensive Cancer Center: Development, Integration, and Implementation is an essential resource for oncology physicians including hematologists, medical oncologists, radiation oncologists, surgical oncologists, and oncology nurses as well as hospitals, health departments, university authorities, governments and legislators. |
| car t cell therapy lymphoma success rate: Cancer Patient Survival National Cancer Institute (U.S.), 1976 |
| car t cell therapy lymphoma success rate: Pediatric Neuro-oncology Katrin Scheinemann, |
| car t cell therapy lymphoma success rate: Cancer Incidence and Survival Among Children and Adolescents , 1999 |
| car t cell therapy lymphoma success rate: SITC’s Guide to Managing Immunotherapy Toxicity Marc S. Ernstoff, MD, Igor Puzanov, MD, MSCI, FACP, Caroline Robert, MD, PhD, Adi M. Diab, MD, Peter M. Hersey, MD, PhD, 2019-03-15 The Society for Immunotherapy of Cancer's handbook,SITC’s Guide to Managing Immunotherapy Toxicity, is a practical reference to managing side effects associated with FDA-approved cancer immunotherapy drugs. Separated into two parts, Part I contains chapter-based overviews of immune checkpoint inhibitors in the clinic, starting with anti-CTLA4 agents, anti-PD1/PD-L1 agents, and approved immunotherapeutic combinations. These chapters cover relevant mechanisms of action, indications, and toxicities seen while combating early, advanced, and metastatic stages in cancer patients. Part II is structured by common and uncommon toxicities that affect major organ sites throughout the body. It begins with a general summary of principles and management options followed by chapters focusing on specific toxicities such as rash and mucosal irritation, muscle and joint toxicity, diarrhea and colitis, pneumonitis, endocrine toxicities, neurological toxicities, cardiac toxicity, renal toxicity, hematologic toxicity, and ocular toxicities. Each chapter provides guidance on how to assess and treat the toxicity and how to support the patient through acute and chronic effects with detailed summary tables for quick reference. Part II concludes with chapters covering management of special patient populations, including patients with autoimmune disease and geriatric patients, treatment and management of fatigue, and a final chapter dedicated to cost effectiveness and the toll of financial toxicity on patients and caregivers. With chapters written by world-recognized leaders in the immuno-oncology field, this text provides thorough coverage of the toxicity and management of adverse effects for immune checkpoint inhibitors. It is an indispensable resource for clinical oncologists, emergency physicians, hospitalists and other medical practitioners in both the hospital and community clinic settings, especially as the use of immune checkpoint inhibitors becomes a fixture in oncology care. Key Features: Outlines strategies for treating high-risk patients facing an acute or chronic side effect to immunotherapy Provides numerous tables that condense and highlight pertinent information for quick reference Describes the various clinical presentations and toxic reactions caused by immunotherapy Purchase includes access to the eBook for use on most mobile devices or computer |
| car t cell therapy lymphoma success rate: Immune Regulation Marc Feldmann, N. A. Mitchison, 2012-12-06 Leukocyte culture conferences have a long pedigree. This volume records some of the scientific highlights of the 16th such annual con ference, and is a witness to the continuing evolution and popularity of leukocyte culture and of immunology. There is strong evidence of the widening horizons of immunology, both technically, with the obviously major impact of molecular biology into our understanding of cellular processes, and also conceptually. Traditionally, the 'proceedings' of these conferences have been published. But have the books produced really recorded the major part of the conference, the informal, friendly, but intense and some times heated exchanges that take place between workers in tackling very similar problems and systems and which are at the heart of every successful conference? Unfortunately this essence cannot be incorpo rated by soliciting manuscripts. For this reason, we have changed the format of publication, retaining published versions of the symposium papers, but requesting the workshop chairmen to produce a summary of the major new observations and areas of controversy highlighted in their sessions, as a vehicle for defining current areas of interest and debate. Not an easy task, as the workshop topics were culled from the abstracts submitted by the participants, rather than being on predefined topics. The unseasonal warmth in Cambridge was reflected in the atmos phere of the conference, the organization of which benefited from the administrative skills of Jean Bacon, Philippa Wells, Mr. Peter Irving, and Mrs. |
| car t cell therapy lymphoma success rate: Cell and Gene Therapies Miguel-Angel Perales, Syed A. Abutalib, Catherine Bollard, 2018-11-27 In this book, experts in the field express their well-reasoned opinions on a range of complex, clinically relevant issues across the full spectrum of cell and gene therapies with the aim of providing trainee and practicing hematologists, including hematopoietic transplant physicians, with information that is relevant to clinical practice and ongoing research. Each chapter focuses on a particular topic, and the concise text is supported by numerous working tables, algorithms, and figures. Whenever appropriate, guidance is provided regarding the availability of potentially high-impact clinical trials. The rapid evolution of cell and gene therapies is giving rise to numerous controversies that need to be carefully addressed. In meeting this challenge, this book will appeal to all residents, fellows, and faculty members responsible for the care of hematopoietic cell transplant patients. It will also offer a robust, engaging tool to aid vital activities in the daily work of every hematology and oncology trainee. |
| car t cell therapy lymphoma success rate: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues World Health Organization, 2001 This is the third volume in the new World Health Organization series on histological and genetic typing of tumours. Tumours of the haematopoietic and lymphoid tissues are covered. This was a collaborative project of the European Association for Haematolpathology and the Society for Haematopathology and others. The WHO classification is based on the principles defined in the Revised European-American Classification of Lymphoid Neoplasms (REAL) classification. Over 50 pathologists from around the world were involved in the project and proponents of all major lymphoma and leukaemia classifications have agreed to accept the WHO as the standard classification of haematological malignancies. So this classification represents the first true world wide concensus of haematologic malignancies. Colour photographs, magnetic resonance and ultrasound images and CT scans are included. |
| car t cell therapy lymphoma success rate: Brain Tumor Imaging Elke Hattingen, Ulrich Pilatus, 2015-09-02 This book describes the basics, the challenges and the limitations of state of the art brain tumor imaging and examines in detail its impact on diagnosis and treatment monitoring. It opens with an introduction to the clinically relevant physical principles of brain imaging. Since MR methodology plays a crucial role in brain imaging, the fundamental aspects of MR spectroscopy, MR perfusion and diffusion-weighted MR methods are described, focusing on the specific demands of brain tumor imaging. The potential and the limits of new imaging methodology are carefully addressed and compared to conventional MR imaging. In the main part of the book, the most important imaging criteria for the differential diagnosis of solid and necrotic brain tumors are delineated and illustrated in examples. A closing section is devoted to the use of MR methods for the monitoring of brain tumor therapy. The book is intended for radiologists, neurologists, neurosurgeons, oncologists and other scientists in the biomedical field with an interest in neuro-oncology. |
| car t cell therapy lymphoma success rate: Immunotherapy of Hepatocellular Carcinoma Tim F. Greten, 2018-08-22 In this book we provide insights into liver – cancer and immunology. Experts in the field provide an overview over fundamental immunological questions in liver cancer and tumorimmunology, which form the base for immune based approaches in HCC, which gain increasing interest in the community due to first promising results obtained in early clinical trials. Hepatocellular carcinoma (HCC) is the third most common cause of cancer related death in the United States. Treatment options are limited. Viral hepatitis is one of the major risk factors for HCC, which represents a typical “inflammation-induced” cancer. Immune-based treatment approaches have revolutionized oncology in recent years. Various treatment strategies have received FDA approval including dendritic cell vaccination, for prostate cancer as well as immune checkpoint inhibition targeting the CTLA4 or the PD1/PDL1 axis in melanoma, lung, and kidney cancer. Additionally, cell based therapies (adoptive T cell therapy, CAR T cells and TCR transduced T cells) have demonstrated significant efficacy in patients with B cell malignancies and melanoma. Immune checkpoint inhibitors in particular have generated enormous excitement across the entire field of oncology, providing a significant benefit to a minority of patients. |
| car t cell therapy lymphoma success rate: Telephone Triage for Oncology Nurses Margaret Hickey, Susan Newton, 2005 |
| car t cell therapy lymphoma success rate: The EBMT Handbook Nicolaus Kröger, Mohamad Mohty, Carlo Dufour, 2020-10-08 This Open Access edition of the European Society for Blood and Marrow Transplantation (EBMT) handbook addresses the latest developments and innovations in hematopoietic stem cell transplantation and cellular therapy. Consisting of 93 chapters, it has been written by 175 leading experts in the field. Discussing all types of stem cell and bone marrow transplantation, including haplo-identical stem cell and cord blood transplantation, it also covers the indications for transplantation, the management of early and late complications as well as the new and rapidly evolving field of cellular therapies. This book provides an unparalleled description of current practices to enhance readers' knowledge and practice skills. This work was published by Saint Philip Street Press pursuant to a Creative Commons license permitting commercial use. All rights not granted by the work's license are retained by the author or authors. |
| car t cell therapy lymphoma success rate: Verbal Perseveration Jacqueline Ann Stark, 2007 Introductory textbooks on neurogenic communication disorders associated with aphasia and brain injury do not provide full documentation of the pervasive influence of perseveration in the diagnosis and treatment of clients with severe language processing deficits. This special issue of Aphasiology aims to revives the profound interest in verbal perseveration observed in the classical German literature between 1890 and 1931. Various aspects of the phenomenon of perseveration are addressed in this issue. When and under what circumstances do perseverations occur? What are the characteristics of perseverative errors and how do they relate to non-perseverative sound and word errors? The papers share a common goal, namely to understand the origin of the phenomenon 'perseveration' in healthy subjects and clients with brain damage and injury. An overarching claim throughout the papers is that perseveration reflects the client's primary language processing deficits. |
| car t cell therapy lymphoma success rate: Population-based Cancer Survival Analysis Paul W. Dickman, Paul C. Lambert, Timo Hakulinen, 2022-12-27 There has been increased interest in studying cancer patient survival in recent years, which has prompted advances in methods for estimating and modeling cancer patient survival. This book is the first focused on this topic, and uses real data and software to illustrate the methods involved. The supporting website provides code to enable readers to reproduce the analysis top illustrate the examples included in the book. The book presents methods for population-based cancer survival analysis, that is, the analysis of patient survival using data collected by population-based cancer registries. The primary focus will be on the statistical methods but non-statistical issues that arise in population-based studies of cancer patient survival, such as registration, coding and classification, and follow up procedures are also discussed. |
| car t cell therapy lymphoma success rate: Lymphocyte Activation L.E. Samelson, H. Renz, 1994 |
| car t cell therapy lymphoma success rate: Lymphoma Ralf Küppers, 2013-01-08 Lymphomas are lymphoid malignancies derived from B or T lymphocytes, and their study has been and still is paradigmatic for many aspects of cancer research. Lymphoma: Methods and Protocols presents and discusses key methods that are used in lymphoma research, partly specific for lymphoma research but often adaptable to the study of other cancers. By covering a broad variety of methods used in lymphoma research, this book will be of interest not only for hematologists, hematopathologists, and immunologists but also for scientists interested in other fields of cancer research as well as human genetics. Written in the highly successful Methods in Molecular BiologyTM series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Versatile and cutting-edge, Lymphoma: Methods and Protocols serves researchers studying human physiology with the ultimate goal of understanding and controlling these often terrible diseases. |
| car t cell therapy lymphoma success rate: Fast Facts: CAR T-Cell Therapy in Diffuse Large B-Cell Lymphoma Richard J. Buka, Dee Moloney, 2021-10-31 Diffuse large B-cell lymphoma (DLBCL) is the most common form of high-grade non-Hodgkin lymphoma. While treatment with immunochemotherapy has generally shown good outcomes, specific subgroups of patients with high-risk disease have an unfavorable prognosis. Extensive efforts have been made to improve outcomes in these patients. As such, CD19-targeted chimeric antigen receptor (CAR) T-cell therapy has become the new standard of care for patients with relapsed or refractory DLBCL after at least two prior lines of therapy. It is an exciting new therapeutic intervention that is integral to the concept of personalized medicine. Table of Contents: • DLBCL: an overview • CAR T cells • CAR T-cell products • Delivering CAR T-cell therapy and managing patient expectations • CAR T-cell therapy-related toxicities |
| car t cell therapy lymphoma success rate: Fast Facts: CAR T-Cell Therapy Richard J. Buka, Ankit J. Kansagra, 2021-02-28 Chimeric antigen receptor (CAR) T cells are genetically engineered immune cells that can seek out and destroy cancer cells. The results from their use in cancer immunotherapy have been very promising, but treatment is often associated with frequent, serious short-term toxicities. 'Fast Facts: CAR-T Therapy' explains what CAR T cells are and how they were developed, discusses the results of clinical trials and the management of toxicities, and outlines future improvements and applications. It is ideal reading for any healthcare professional wanting to know more about this exciting therapeutic field. Table of Contents: • CAR T cells • Clinical application • Practical aspects • Future directions |
| car t cell therapy lymphoma success rate: CAR T-Cell, An Issue of Hematology/Oncology Clinics of North America, E-Book Caron A Jacobson, Parth S. Shah, 2023-10-12 In this issue of Hematology/Oncology Clinics, guest editors Drs. Caron A. Jacobson and Parth S. Shah bring their considerable expertise to the topic of CAR T-Cell Therapy. Top experts in the field discuss the multiple ways CAR T-cell therapy can be used to help fight a variety of cancers, such as diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, mantle cell lymphoma, multiple myeloma, and B-cell acute lymphoblastic leukemia (ALL). - Contains 12 practice-oriented topics including CAR T-cells in aggressive B-cell lymphomas; CAR T-cells in multiple myeloma; CAR T-cells in AML; mechanisms of resistance of CAR T-cell therapy; the role of CAR T-cell therapy in the era of bispecific antibodies; and more. - Provides in-depth clinical reviews on CAR T-cell therapy, offering actionable insights for clinical practice. - Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews. |
CAR T-Cell Therapy for Relapsed/ Refractory Non-Hodgkin’s …
CD19-specific chimeric antigen receptor (CAR) T-cell therapy has revolutionized treatment for patients who have R/R aggressive B-cell NHL, with overall response rates (ORRs) ranging …
CAR-T Cell Therapy for Lymphoma: How Does Radiation …
Rare patients with limited-stage disease can be salvaged with RT alone, but success rates are low.
CAR-T Cell Therapies: How much for survival? - Cancer
Currently, there is more than 200 ongoing clinical trials on CAR-T therapies, primarily to cure haematological cancers (lymphoma, leukaemia and myeloma), but also solid tumours (e.g. …
CAR T cell combination therapies to treat cancer - Cell Press
Chimeric antigen receptor (CAR) T cell therapy utilizes engineered T cells to target specific tumor antigens, demon-strating high efficacy and gaining FDA approval in some hematological malig …
CAR T-Cell Therapy for Lymphoma Fact Sheet - cinj.org
CAR T-cell therapies that target CD19, CD20, CD22, and CD30 are in development for patients with lymphoma and chronic lymphocytic leukemia (CLL). Several CAR T-cell therapies are in …
The Improving Outcomes in Relapsed-Refractory Diffuse …
These data present the unmet need in the field, and this review article focuses on how second-generation chimeric antigen receptor T (CAR T) cell therapy targeting CD19 antigen may …
CAR T-cell therapy: a summary of evidence - Sax Institute
Promising results have been seen for CAR T-cell therapy as a treatment for leukaemia and lymphoma, which has led to accelerated regulatory approvals and rapid proliferation of trials …
Facts About Chimeric Antigen Receptor (CAR) T-Cell Therapy
Autologous chimeric antigen receptor (CAR) T-cell therapy for the treatment of hematologic malignancies has generated intense interest from patients, families and healthcare providers. …
CAR T Cells for Mantle Cell Lymphoma:
ZUMA-2 investigators report results of a multicenter, phase 2 clinical trial with an anti-CD19 chimeric antigen receptor (19-28z) modified T cell (CAR T) product (KTE-X19). KTE-X19 …
Driving the next wave of innovation in CAR T-cell therapies
Unlocking the full potential of CAR T-cell therapies requires investment in four areas. therapies have demonstrated the potential to disrupt cancer care—but its application is currently limited …
Enhanced CAR T-Cell Therapy for Lymphoma after Previous …
Chimeric antigen receptor (CAR) T cells targeting CD19 have transformed the treat-ment of B-cell cancers, but many patients do not have long-term remission. We de-signed an anti-CD19 …
CAR T cell therapy: looking back and looking forward - Nature
Both studies demonstrated improved event-free survival for CD19-directed CAR T cell therapy compared to a standard of care involving chemotherapy followed by autologous stem cell...
Second-line Treatment With CAR T-Cell Therapy for Large B …
Herein, we review the 3 landmark clinical trials (ZUMA-7, BELINDA, and TRANSFORM) exploring second-line use of CAR T-cell therapy compared with SOC therapy in the primary refractory …
Safety and Toxicity Profiles of CAR T Cell Therapy in Non …
CAR T cell therapy has improved outcomes for patients with NHL with varied and unpredictable toxicity. In this systematic review and meta-analysis, we found that rates of CRS and ICANS …
CD19 CAR T Cells Expressing IL-12 Eradicate Lymphoma in …
Chimeric antigen receptor (CAR) T cell therapy represents a sig-nificant advancement in cancer therapy. Larger studies have shown 90% complete remission rates against chemoresistant …
CAR T-cell therapy versus allogeneic HSCT for relapsed or …
Overall response rate was 91% (95% CI 81·8–96·7), complete response rate was 68% (55·2–78·5), and the rates were consistent among high-risk subgroups. At a median follow-up …
CAR T cell therapy - lymphoma-action.org.uk
In CAR T-cell therapy, your own T cells are collected and genetically modified (changed) in a laboratory. These changes allow them to recognise and kill lymphoma cells that are otherwise …
CAR-T cell therapy for hematological malignancies: History, …
Jul 8, 2023 · Six CAR-T cell therapies have been granted approval for hematological cancers by the Food and Drug Administration since 2017. Four out of six CAR-T cell products are anti …
CAR T-cell therapy for indolent lymphoma: a new treatment …
In The Lancet Oncology, Caron A Jacobson and colleagues1 report the results of the ZUMA-5 trial, a multicentre, single-arm, phase 2 study of axicabtagene ciloleucel for treatment of …
Optimizing CAR-T Cell Manufacturing Processes during
Tisagenlecleucel is a CD19-specific chimeric antigen receptor (CAR)-T cell therapy approved for patients aged %25 years with relapsed or refractory B cell precursor acute lymphoblastic …
CAR T-Cell Therapy for Relapsed/ Refractory Non-Hodgkin’s …
CD19-specific chimeric antigen receptor (CAR) T-cell therapy has revolutionized treatment for patients who have R/R aggressive B-cell NHL, with overall response rates (ORRs) ranging …
CAR-T Cell Therapy for Lymphoma: How Does Radiation …
Rare patients with limited-stage disease can be salvaged with RT alone, but success rates are low.
CAR-T Cell Therapies: How much for survival? - Cancer
Currently, there is more than 200 ongoing clinical trials on CAR-T therapies, primarily to cure haematological cancers (lymphoma, leukaemia and myeloma), but also solid tumours (e.g. …
CAR T cell combination therapies to treat cancer - Cell Press
Chimeric antigen receptor (CAR) T cell therapy utilizes engineered T cells to target specific tumor antigens, demon-strating high efficacy and gaining FDA approval in some hematological malig …
CAR T-Cell Therapy for Lymphoma Fact Sheet - cinj.org
CAR T-cell therapies that target CD19, CD20, CD22, and CD30 are in development for patients with lymphoma and chronic lymphocytic leukemia (CLL). Several CAR T-cell therapies are in …
The Improving Outcomes in Relapsed-Refractory Diffuse …
These data present the unmet need in the field, and this review article focuses on how second-generation chimeric antigen receptor T (CAR T) cell therapy targeting CD19 antigen may …
CAR T-cell therapy: a summary of evidence - Sax Institute
Promising results have been seen for CAR T-cell therapy as a treatment for leukaemia and lymphoma, which has led to accelerated regulatory approvals and rapid proliferation of trials …
Facts About Chimeric Antigen Receptor (CAR) T-Cell Therapy
Autologous chimeric antigen receptor (CAR) T-cell therapy for the treatment of hematologic malignancies has generated intense interest from patients, families and healthcare providers. …
CAR T Cells for Mantle Cell Lymphoma:
ZUMA-2 investigators report results of a multicenter, phase 2 clinical trial with an anti-CD19 chimeric antigen receptor (19-28z) modified T cell (CAR T) product (KTE-X19). KTE-X19 …
Driving the next wave of innovation in CAR T-cell therapies
Unlocking the full potential of CAR T-cell therapies requires investment in four areas. therapies have demonstrated the potential to disrupt cancer care—but its application is currently limited …
Enhanced CAR T-Cell Therapy for Lymphoma after Previous …
Chimeric antigen receptor (CAR) T cells targeting CD19 have transformed the treat-ment of B-cell cancers, but many patients do not have long-term remission. We de-signed an anti-CD19 …
CAR T cell therapy: looking back and looking forward - Nature
Both studies demonstrated improved event-free survival for CD19-directed CAR T cell therapy compared to a standard of care involving chemotherapy followed by autologous stem cell...
Second-line Treatment With CAR T-Cell Therapy for Large B …
Herein, we review the 3 landmark clinical trials (ZUMA-7, BELINDA, and TRANSFORM) exploring second-line use of CAR T-cell therapy compared with SOC therapy in the primary refractory …
Safety and Toxicity Profiles of CAR T Cell Therapy in Non …
CAR T cell therapy has improved outcomes for patients with NHL with varied and unpredictable toxicity. In this systematic review and meta-analysis, we found that rates of CRS and ICANS …
CD19 CAR T Cells Expressing IL-12 Eradicate Lymphoma in …
Chimeric antigen receptor (CAR) T cell therapy represents a sig-nificant advancement in cancer therapy. Larger studies have shown 90% complete remission rates against chemoresistant …
CAR T-cell therapy versus allogeneic HSCT for relapsed or …
Overall response rate was 91% (95% CI 81·8–96·7), complete response rate was 68% (55·2–78·5), and the rates were consistent among high-risk subgroups. At a median follow-up …
CAR T cell therapy - lymphoma-action.org.uk
In CAR T-cell therapy, your own T cells are collected and genetically modified (changed) in a laboratory. These changes allow them to recognise and kill lymphoma cells that are otherwise …
CAR-T cell therapy for hematological malignancies: History, …
Jul 8, 2023 · Six CAR-T cell therapies have been granted approval for hematological cancers by the Food and Drug Administration since 2017. Four out of six CAR-T cell products are anti …
CAR T-cell therapy for indolent lymphoma: a new treatment …
In The Lancet Oncology, Caron A Jacobson and colleagues1 report the results of the ZUMA-5 trial, a multicentre, single-arm, phase 2 study of axicabtagene ciloleucel for treatment of …
Optimizing CAR-T Cell Manufacturing Processes during
Tisagenlecleucel is a CD19-specific chimeric antigen receptor (CAR)-T cell therapy approved for patients aged %25 years with relapsed or refractory B cell precursor acute lymphoblastic …
